Inequalities have rendered global economy more fragile: UNCTAD (See 'Brief') Gangwar terms three Labour Codes as Game-Changer (See 'Brief') Companies Act - Provisos to Ss 164(2) and 167(1)(a) of Companies Act, 2013 can operate retrospectively: HC (See 'Legal Desk') IBC - Mere debt being due and payable in law is sufficient to justify initiation of Corporate Insolvency Resolution Process at instance of Financial Creditor: NCLAT (See 'Legal Desk') NCLAT (Recruitment, Salary and other Terms and Conditions of Service of Staff Car Drivers) Rules, 2020 (See 'Dashboard') Parliament passes Essential Commodities Amendment) Bill, 2020 (See 'Brief') Haryana enacts law ( Haryana Development and Regulation of Urban Areas (second amendment and validation) Bill, 2020 ) to validate de-licensing of land OYO Hotels & Homes, appoints Tejal Patil as Senior Legal Advisor for India & South Asia Huawei Technologies continue to cut staff numbers and investment in Australia amid strained relations between Beijing and Canberra Indian cold chain operators to prepare an efficient logistics network to ensure smooth delivery of covid-19 vaccines to its more than 1.3 billion people Companies Act - Period of limitation of 45 days prescribed in Section 421(3) starts running only from date on which copy of order of Tribunal is made available to person aggrieved: SC (See 'Legal Desk') IBC - In case of both parties being joint development partners, any claim by one of partners does not qualify as Financial Debt: NCLT (See 'Legal Desk')

CCI olays 20% equity buy of Piramal Pharma by Clover Investments

Published: Sep 12, 2020


NEW DELHI, SEPT 12, 2020: The Competition Commission of India (CCI) approves proposed combination involving acquisition of 20% of the issued and paid-up equity share capital of Piramal Pharma Limited (Pharma Co.) by CA Clover Intermediate II Investments (Curie).

The proposed combination relates to (i) the transfer of global pharmaceutical business ( Transferred Business ) by Piramal Enterprises Limited ( PEL ) to a wholly owned subsidiary of PEL, i.e. Pharma Co., followed by, (ii) the acquisition of 20% of the issued and paid-up equity share capital of Pharma Co. by Curie ( Proposed Combination ).

Curie is a special purpose acquisition vehicle, owned and controlled by investment funds advised by the affiliates of the Carlyle Group Inc. (“ Carlyle Group ”).

The Carlyle Group is a global alternative asset manager, which manages funds that invest globally across four investment disciplines: (i) Corporate Private Equity (buyout and growth capital), (ii) Real Assets (real estate, infrastructure and energy and renewable resources), (iii) Global Credit (leveraged loans and structured credit, opportunistic credit, energy credit, private credit and distressed credit), and (iv) Solutions (private equity fund of funds program and related co-investment and secondary activities).

Pharma Co. is a wholly owned entity of PEL that will hold PEL's Transferred Business as part of the Proposed Combination, and acquire the pharmaceutical business of PEL comprising the Contract Development and Manufacturing Organisation ( CDMO ), Complex Hospital Generics ( CHG ), and Consumer Healthcare Division ( CHD )segments, as well as equity interest in certain PEL entities.